Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Keytruda Retains Top Spot in Japan Drug Ranking in June: Encise
July 7, 2021
- Sosei Teams Up with InveniAI on GPCR-Targeted Drug Discovery
July 7, 2021
- Astellas Revamping Sales Organization as Product Mix Shifts towards Specialty Area: CEO
July 6, 2021
- CEO Says Astellas Pivoting to Specialty Drugs, Going Global: Full Interview
July 6, 2021
- Sagent Jettisons Camostat Mesilate for COVID-19 after PII Miss: Nichi-Iko
July 6, 2021
- Reps’ Face-to-Face Meetings Up 76.1% YOY in May: Intage
July 6, 2021
- All Ranitidine Tablet Drugs to Be Discontinued in Japan over Carcinogen Woes
July 5, 2021
- Astellas Begins COVID-19 Vaccination Program
July 5, 2021
- Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
- 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
- Ayumi to Leverage IT to Boost Sales and Marketing, Eyes More Licensing Deals
July 2, 2021
- Towa Now Curbs Shipments for 235 Products; 27 Added to Restriction List
July 2, 2021
- Kaken Grants European Rights for Efinaconazole to Almirall
July 2, 2021
- Mitsubishi Tanabe Rolls Out Oral Film ALS Drug in US
July 2, 2021
- Ex-BMS Exec Tsuji Takes Reins of Mundipharma Japan
July 2, 2021
- Solasia Files NDA for PTCL Drug in Japan
July 2, 2021
- Shionogi’s Chinese JV Commences RWD Collection, Analysis of Metabolic Diseases
July 2, 2021
- Takeda Revises Rules to Enable Fully Virtual Shareholders Meetings
July 1, 2021
- Nichi-Iko Expects Shipment Controls to Linger beyond April Next Year for 110 Products
July 1, 2021
- Eisai’s Sleep Inducer Dayvigo Now Available in Hong Kong
July 1, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…